CRESCENT BIOPHARMA, INC. (CBIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth No data.
6/24
1.3 / 5 stars
All 24 Win/Lose results and 96 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 3 losses, 8 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/1 |
LoseCBIO / S&P -2.01% / 15.20% |
No dataCBIO / S&P / 15.00% |
No dataCBIO / S&P / 50.40% |
| 2026-Q11/1 |
WinCBIO / S&P 54.89% / -4.33% |
No dataCBIO / S&P / 11.30% |
No dataCBIO / S&P / 27.70% |
| 2025-Q40/1 |
LoseCBIO / S&P -0.25% / 2.65% |
No dataCBIO / S&P / 9.00% |
No dataCBIO / S&P / 13.40% |
| 2025-Q30/1 |
LoseCBIO / S&P -26.33% / 8.12% |
No dataCBIO / S&P / 4.61% |
No dataCBIO / S&P / 13.45% |
| 2025-Q20/1 |
LoseCBIO / S&P -23.14% / 10.94% |
No dataCBIO / S&P / 4.83% |
No dataCBIO / S&P / 10.63% |
| 2025-Q10/1 |
LoseCBIO / S&P -16.00% / -4.27% |
No dataCBIO / S&P / 4.98% |
No dataCBIO / S&P / 10.57% |
| 2024-Q41/2 |
WinCBIO / S&P 47.06% / 2.41% |
No dataCBIO / S&P / 5.25% |
LoseCBIO / S&P -20.69% / 6.15% |
| 2024-Q30/2 |
LoseCBIO / S&P -39.29% / 5.89% |
No dataCBIO / S&P / 5.89% |
LoseCBIO / S&P -22.22% / 6.11% |
| 2024-Q20/2 |
LoseCBIO / S&P -90.67% / 4.28% |
No dataCBIO / S&P / 5.38% |
LoseCBIO / S&P -26.15% / 5.12% |
| 2024-Q11/2 |
WinCBIO / S&P 27.12% / 10.56% |
No dataCBIO / S&P / 5.71% |
LoseCBIO / S&P -41.56% / 5.59% |
| 2023-Q41/2 |
WinCBIO / S&P 57.33% / 11.69% |
No dataCBIO / S&P / 6.81% |
LoseCBIO / S&P -34.09% / 7.78% |
| 2023-Q30/2 |
LoseCBIO / S&P -13.79% / -3.27% |
No dataCBIO / S&P / 7.52% |
LoseCBIO / S&P -38.24% / -5.03% |
| 2023-Q21/2 |
WinCBIO / S&P 38.10% / 8.74% |
No dataCBIO / S&P / 9.50% |
LoseCBIO / S&P -45.83% / -8.57% |
| 2023-Q10/2 |
LoseCBIO / S&P -54.64% / 7.50% |
No dataCBIO / S&P / 10.77% |
LoseCBIO / S&P -37.40% / -15.69% |
| 2022-Q41/2 |
WinCBIO / S&P 450.91% / 7.56% |
No dataCBIO / S&P / 11.88% |
LoseCBIO / S&P -28.46% / -17.99% |
| 2022-Q30/0 |
No dataCBIO / S&P / -4.88% |
No dataCBIO / S&P / 13.47% |
No dataCBIO / S&P / -1.41% |
| 2022-Q20/0 |
No dataCBIO / S&P / -16.10% |
No dataCBIO / S&P / 13.71% |
No dataCBIO / S&P / 11.04% |
| 2022-Q10/0 |
No dataCBIO / S&P / -4.60% |
No dataCBIO / S&P / 15.97% |
No dataCBIO / S&P / 42.23% |
| 2021-Q40/0 |
No dataCBIO / S&P / 11.03% |
No dataCBIO / S&P / 15.00% |
No dataCBIO / S&P / 96.40% |
| 2021-Q30/0 |
No dataCBIO / S&P / 0.58% |
No dataCBIO / S&P / 10.77% |
No dataCBIO / S&P / 69.42% |
| 2021-Q20/0 |
No dataCBIO / S&P / 8.55% |
No dataCBIO / S&P / 6.58% |
No dataCBIO / S&P / 51.81% |
| 2021-Q10/0 |
No dataCBIO / S&P / 6.17% |
No dataCBIO / S&P / -1.06% |
No dataCBIO / S&P / 7.39% |
| 2020-Q40/0 |
No dataCBIO / S&P / 12.15% |
No dataCBIO / S&P / -3.72% |
No dataCBIO / S&P / -33.42% |
| 2020-Q30/0 |
No dataCBIO / S&P / 8.93% |
No dataCBIO / S&P / -2.04% |
No dataCBIO / S&P / -27.10% |
| 2020-Q20/0 |
No dataCBIO / S&P / 20.54% |
No dataCBIO / S&P / -0.46% |
No dataCBIO / S&P / -27.11% |
| 2020-Q10/0 |
No dataCBIO / S&P / -19.60% |
No dataCBIO / S&P / 3.47% |
No dataCBIO / S&P / -14.75% |
| 2019-Q40/0 |
No dataCBIO / S&P / 9.07% |
No dataCBIO / S&P / 5.36% |
No dataCBIO / S&P / 2.99% |
| 2019-Q30/0 |
No dataCBIO / S&P / 1.70% |
No dataCBIO / S&P / 5.02% |
No dataCBIO / S&P / 0.21% |
| 2019-Q20/0 |
No dataCBIO / S&P / 4.30% |
No dataCBIO / S&P / 6.64% |
No dataCBIO / S&P / 8.65% |
| 2019-Q10/0 |
No dataCBIO / S&P / 13.65% |
No dataCBIO / S&P / 8.12% |
No dataCBIO / S&P / 14.29% |
| 2018-Q40/0 |
No dataCBIO / S&P / -13.52% |
No dataCBIO / S&P / 9.05% |
No dataCBIO / S&P / 18.23% |
| 2018-Q30/0 |
No dataCBIO / S&P / 7.71% |
No dataCBIO / S&P / 10.21% |
No dataCBIO / S&P / 19.06% |
| 2018-Q20/0 |
No dataCBIO / S&P / 3.43% |
No dataCBIO / S&P / 9.03% |
No dataCBIO / S&P / 14.46% |
| 2018-Q10/0 |
No dataCBIO / S&P / -0.76% |
No dataCBIO / S&P / 7.68% |
No dataCBIO / S&P / 12.46% |
| 2017-Q40/0 |
No dataCBIO / S&P / 6.64% |
No dataCBIO / S&P / 7.03% |
No dataCBIO / S&P / 13.82% |
| 2017-Q30/0 |
No dataCBIO / S&P / 4.48% |
No dataCBIO / S&P / 5.68% |
No dataCBIO / S&P / 17.57% |
| 2017-Q20/0 |
No dataCBIO / S&P / 3.09% |
No dataCBIO / S&P / 4.83% |
No dataCBIO / S&P / 17.74% |
| 2017-Q10/0 |
No dataCBIO / S&P / 6.07% |
No dataCBIO / S&P / 3.67% |
No dataCBIO / S&P / 13.32% |
| 2016-Q40/0 |
No dataCBIO / S&P / 3.82% |
No dataCBIO / S&P / 2.09% |
No dataCBIO / S&P / 7.05% |
| 2016-Q30/0 |
No dataCBIO / S&P / 3.85% |
No dataCBIO / S&P / 0.20% |
No dataCBIO / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 23.33% | 20.78% |
| Annualized return | 23.33% | 20.78% |
5Y · 2022-09-21 to 2026-08-27
| Metric | CBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -69.73% | 83.14% |
| Annualized return | -21.26% | 12.86% |
10Y · 2022-09-21 to 2026-08-27
| Metric | CBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -69.73% | 319.30% |
| Annualized return | -11.26% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |